Prognostic value of circulating inflammatory factors in non-small cell lung cancer: A systematic review and meta-analysis

Cancer Biomarkers

Volumn 14, Issue 6, 2014, Pages 469-481

  Liao, Chen ^a   Yu, Zubin ^a   Guo, Wei ^b   Liu, Qingyun ^a   Wu, Yanan ^a   Li, Yafei ^a   Bai, Li ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

C reactive protein; Circulating inflammatory factor; Interleukin 6; Non small cell lung cancer; Prognosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; HUMAN; LUNG LOBECTOMY; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; GENETICS; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR EMBOLISM;

C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908137451     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-140423     Document Type: Article

References (46)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward and D. Forman, Global cancer statistics, CA Cancer J Clin 61 (2011), 69-90.
2. L. Esposito, D. Conti, R. Ailavajhala, N. Khalil and A. Giordano, Lung Cancer: Are we up to the Challenge?, Curr Genomics 11 (2010), 513-518.
3. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum and D.H. Johnson, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med 355 (2006), 2542-2550.
4. B.B. Oven Ustaalioglu, O.U. Unal, N. Turan, A. Bilici, S. Kaya, T. Eren, A. Ulas, A. Inal, V. Berk, U. Demirci, S. Alici, O. Bal, M. Benekli and M. Gumus, Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences, Asian Pac J Cancer Prev 14 (2013), 6287-92.
5. L.M. Coussens and Z. Werb, Inflammation and cancer, Nature 420 (2002), 860-867.
6. S.R. Pine, L.E. Mechanic, L. Enewold, A.K. Chaturvedi, H.A. Katki, Y.-L. Zheng, E.D. Bowman, E.A. Engels, N.E. Caporaso and C.C. Harris, Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer, J Natl Cancer Inst 103 (2011), 1112-1122.
7. M. Crohns, S. Saarelainen, S. Laine, T. Poussa, H. Alho and P. Kellokumpu-Lehtinen, Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival, Cytokine 50 (2010), 30-6.
8. M. Tomita, T. Shimizu, T. Ayabe, K. Nakamura and T. Onitsuka, Elevated preoperative inflammatory markers based on neutrophil-to-lymphocyte ratio and C-reactive protein predict poor survival in resected non-small cell lung cancer, Anticancer Res 32 (2012), 3535-8.
9. H. Ujiie, M. Tomida, H. Akiyama, Y. Nakajima, D. Okada, N. Yoshino, Y. Takiguchi and H. Tanzawa, Serum Hepatocyte Growth Factor and Interleukin-6 Are Effective Prognostic Markers for Non-small Cell Lung Cancer, Anticancer Res 32 (2012), 3251-3258.
10. C. Dehing-Oberije, H. Aerts, S.P. Yu, D. De Ruysscher, P. Menheere, M. Hilvo, H. van der Weide, B. Rao and P. Lambin, Development and Validation of a Prognostic Model Using Blood Biomarker Information for Prediction of Survival of Non Small-Cell Lung Cancer Patients Treated with Combined Chemotherapy and Radiation or Radiotherapy Alone (Nct00181519, Nct00573040, and Nct00572325), Int J Radiat Oncol 81 (2011), 360-368.
11. E. Koh, T. Iizasa, H. Yamaji, Y. Sekine, K. Hiroshima, I. Yoshino and T. Fujisawa, Significance of the Correlation Between the Expression of Interleukin 6 and Clinical Features in Patients With Non-Small Cell Lung Cancer, Int J Surg Pathol 20 (2012), 233-239.
12. D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe and S.B. Thacker, Meta-analysis of observational studies in epidemiology: A proposal for reporting, Jama 283 (2000), 2008-2012.
13. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett and M.R. Sydes, Practical methods for incorporating summary time-to-event data into meta-analysis, Trials 8 (2007), 16.
14. J. Little, L. Bradley, M.S. Bray, M. Clyne, J. Dorman, D.L. Ellsworth, J. Hanson, M. Khoury, J. Lau and T.R. O'Brien, Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations, Am J Epidemiol 156 (2002), 300-310.
15. E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A.-P. Meert, F. Vallot, J.-J. Lafitte and J.-P. Sculier, Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis, Eur Respir J 18 (2001), 705-719.
16. J.P. Higgins, S.G. Thompson, J.J. Deeks and D.G. Altman, Measuring inconsistency in meta-analyses, BMJ 327 (2003), 557.
17. C.B. Begg and M. Mazumdar, Operating characteristics of a rank correlation test for publication bias, Biometrics 50 (1994), 1088-101.
18. M. Alifano, P.E. Falcoz, V. Seegers, N. Roche, O. Schussler, M. Younes, F. Antonacci, P. Forgez, A. Dechartres, G. Massard, D. Damotte and J.F. Regnard, Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer, J Thorac Cardiov Sur 142 (2011), 1161-1167.
19. K.H. Allin, S.E. Bojesen and B.G. Nordestgaard, Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer, J Clin Oncol 27 (2009), 2217-2224.
20. B. Gagnon, M. Abrahamowicz, Y. Xiao, M.E. Beauchamp, N. MacDonald, G. Kasymjanova, H. Kreisman and D. Small, Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer, Br J Cancer 102 (2010), 1113-22.
21. M. Hara, A. Yonei, T. Ayabe, M. Tomita, K. Nakamura and T. Onitsuka, Postoperative serum C-reactive protein levels in non-small cell lung cancer patients, Ann Thorac Cardiovasc Surg 16 (2010), 85-90.
22. N. Katsumata, K. Eguchi, M. Fukuda, N. Yamamoto, Y. Ohe, F. Oshita, T. Tamura, T. Shinkai and N. Saijo, Serum levels of cytokines in patients with untreated primary lung cancer, Clin Cancer Res 2 (1996), 553-9.
23. A. Koch, H. Fohlin and S. Sorenson, Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy, J Thorac Oncol 4 (2009), 326-332.
24. K. Masago, S. Fujita, Y. Togashi, Y.H. Kim, Y. Hatachi, A. Fukuhara, H. Nagai, K. Irisa, Y. Sakamori, C. Okuda, T. Mio and M. Mishima, Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, nonsmall cell lung cancer who received gefitinib, Oncology 79 (2010), 355-62.
25. C. O'Dowd, L.A. McRae, D.C. McMillan, A. Kirk and R. Milroy, Elevated Preoperative C-reactive Protein Predicts Poor Cancer Specific Survival in Patients Undergoing Resection for Non-small Cell Lung Cancer, J Thorac Oncol 5 (2010), 988-992.
26. H.R. Scott, D.C. McMillan, L.M. Forrest, D.J. Brown, C.S. McArdle and R. Milroy, The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer, Br J Cancer 87 (2002), 264-7.
27. P.J. Vlachostergios, I. Gioulbasanis, K. Kamposioras, P. Georgoulias, V.E. Baracos, S. Ghosh, E. Maragouli, V. Georgoulias and C.N. Papandreou, Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients, Oncology 81 (2011), 113-8.
28. S. Wilop, M. Crysandt, M. Bendel, A.H. Mahnken, R. Osieka and E. Jost, Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer, Onkologie 31 (2008), 665-670.
29. C.H. Chang, C.F. Hsiao, Y.M. Yeh, G.C. Chang, Y.H. Tsai, Y.M. Chen, M.S. Huang, H.L. Chen, Y.J. Li, P.C. Yang, C.J. Chen, C.A. Hsiung and W.C. Su, Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy, Int J Cancer 132 (2013), 1977-1985.
30. L. Enewold, L.E. Mechanic, E.D. Bowman, Y.L. Zheng, Z.P. Yu, G. Trivers, A.J. Alberg and C.C. Harris, Serum Concentrations of Cytokines and Lung Cancer Survival in African Americans and Caucasians, Cancer Epidemiol Biomarkers Prev 18 (2009), 215-222.
31. F. Martin, F. Santolaria, N. Batista, A. Milena, E. Gonzalez-Reimers, M.J. Brito and J. Oramas, Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer, Cytokine 11 (1999), 80-6.
32. K. Sanchez-Lara, J.G. Turcott, E. Juarez, P. Guevara, C. Nunez-Valencia, L.F. Onate-Ocana, D. Flores and O. Arrieta, Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study, Nutr Cancer 64 (2012), 526-534.
33. N. Songur, B. Kuru, F. Kalkan, C. Ozdilekcan, H. Cakmak and N. Hizel, Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer, Tumori 90 (2004), 196-200.
34. F. De Vita, M. Orditura, G. Galizia, C. Romano, A. Roscigno, E. Lieto and G. Catalano, Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients, Chest 117 (2000), 365-373.
35. C. Su, C. Zhou, S. Zhou and J. Xu, Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival, Med Oncol 28 (2011), 1453-7.
36. W.W. Lin and M. Karin, A cytokine-mediated link between innate immunity, inflammation, and cancer, J Clin Invest 117 (2007), 1175-1183.
37. S. Black, I. Kushner and D. Samols, C-reactive protein, J Biol Chem 279 (2004), 48487-48490.
38. Y. Kanoh, T. Abe, N. Masuda and T. Akahoshi, Progression of non-small cell lung cancer: Diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A, Oncol Rep 29 (2013), 469-473.
39. K. Heikkila, S. Ebrahim and D.A. Lawlor, A systematic review of the association between circulating concentrations of C reactive protein and cancer, J Epidemiol Community Health 61 (2007), 824-832.
40. H. Yamaji, T. Iizasa, E. Koh, M. Suzuki, M. Otsuji, H. Chang, S. Motohashi, S. Yokoi, K. Hiroshima and M. Tagawa, Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer, Cancer Immunol Immunother 53 (2004), 786-792.
41. J.G. Lee, B.C. Cho, M.K. Bae, C.Y. Lee, I.K. Park, D.J. Kim, S.V. Ahn and K.Y. Chung, Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer, Lung Cancer 63 (2009), 106-110.
42. A.J. Staal-van den Brekel, M.A. Dentener, A. Schols, W.A. Buurman and E. Wouters, Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients, J Clin Oncol 13 (1995), 2600-2605.
43. T. Blankenstein, The role of tumor stroma in the interaction between tumor and immune system, Curr Opin Immunol 17 (2005), 180-186.
44. P. Rybojad, A. Jablonka, B. Wilczynska and J. Tabarkiewicz, Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer, Eur J Surg Oncol 39 (2013), 1269-77.
45. P.W. Szlosarek and F.R. Balkwill, Tumour necrosis factor alpha: A potential target for the therapy of solid tumours, Lancet Oncol 4 (2003), 565-573.
46. D. Derin, H.O. Soydinc, N. Guney, F. Tas, H. Camlica, D. Duranyildiz, V. Yasasever and E. Topuz, Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer, Lung Cancer 59 (2008), 240-245.